IVERIC bio, Inc. (ISEE): Price and Financial Metrics

IVERIC bio, Inc. (ISEE): $13.63

0.25 (+1.87%)

POWR Rating

Component Grades













Add ISEE to Watchlist
Sign Up

Industry: Biotech



in industry

ISEE Stock Price Chart Interactive Chart >

Price chart for ISEE

ISEE Price/Volume Stats

Current price $13.63 52-week high $19.34
Prev. close $13.38 52-week low $8.37
Day low $13.24 Volume 2,061,000
Day high $13.90 Avg. volume 1,792,740
50-day MA $10.85 Dividend yield N/A
200-day MA $13.97 Market Cap 1.61B

IVERIC bio, Inc. (ISEE) Company Bio

IVERIC bio, Inc. (formerly Ophthotech Corporation) is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). The company was founded in 2007 and is based in New York, New York.

ISEE Latest News Stream

Event/Time News Detail
Loading, please wait...

ISEE Latest Social Stream

Loading social stream, please wait...

View Full ISEE Social Stream

Latest ISEE News From Around the Web

Below are the latest news stories about IVERIC bio Inc that investors may wish to consider to help them evaluate ISEE as an investment opportunity.

IVERIC bio, Inc. (ISEE) Q4 2021 Earnings Call Transcript

Representing IVERIC bio today are Mr. Glenn Sblendorio, chief executive officer; Dr. Pravin Dugel, president; Mr. And we are pleased to welcome Mr. Tony Gibney as chief business and strategy officer.

Yahoo | February 24, 2022

Iveric Bio Reports Fourth Quarter and Full Year 2021 Operational Highlights and Financial Results

PARSIPPANY, N.J., February 24, 2022--Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2021 and provided a general business update.

Yahoo | February 24, 2022

Iveric Bio to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022

NEW YORK, February 17, 2022--Iveric Bio announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, February 24, 2022.

Yahoo | February 17, 2022

Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

In this article, we discuss the top 10 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. You can skip our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, and go directly to the Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Dr. Srinivas Akkaraju […]

Yahoo | February 17, 2022

Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

NEW YORK, February 11, 2022--Iveric Bio announced a post-hoc analysis from the GATHER1 Zimura Phase 3 clinical trial, which evaluated various GA growth parameters.

Yahoo | February 11, 2022

Read More 'ISEE' Stories Here

ISEE Price Returns

1-mo 20.41%
3-mo 37.12%
6-mo -11.38%
1-year 41.98%
3-year 1,055.08%
5-year 434.51%
YTD -18.48%
2021 141.97%
2020 -19.46%
2019 615.00%
2018 -61.54%
2017 -35.40%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.4437 seconds.